title: Low-energy extracorporeal shock wave therapy for promotion of vascular endothelial growth factor expression and angiogenesis and improvement of locomotor and sensory functions after spinal cord injury.
abstract: OBJECTIVE Extracorporeal shock wave therapy (ESWT) is widely used to treat various human diseases. Low-energy ESWT increases expression of vascular endothelial growth factor (VEGF) in cultured endothelial cells. The VEGF stimulates not only endothelial cells to promote angiogenesis but also neural cells to induce neuroprotective effects. A previous study by these authors demonstrated that low-energy ESWT promoted expression of VEGF in damaged neural tissue and improved locomotor function after spinal cord injury (SCI). However, the neuroprotective mechanisms in the injured spinal cord produced by low-energy ESWT are still unknown. In the present study, the authors investigated the cell specificity of VEGF expression in injured spinal cords and angiogenesis induced by low-energy ESWT. They also examined the neuroprotective effects of low-energy ESWT on cell death, axonal damage, and white matter sparing as well as the therapeutic effect for improvement of sensory function following SCI. METHODS Adult female Sprague-Dawley rats were divided into the SCI group (SCI only) and SCI-SW group (low-energy ESWT applied after SCI). Thoracic SCI was produced using a New York University Impactor. Low-energy ESWT was applied to the injured spinal cord 3 times a week for 3 weeks after SCI. Locomotor function was evaluated using the Basso, Beattie, and Bresnahan open-field locomotor score for 42 days after SCI. Mechanical and thermal allodynia in the hindpaw were evaluated for 42 days. Double staining for VEGF and various cell-type markers (NeuN, GFAP, and Olig2) was performed at Day 7; TUNEL staining was also performed at Day 7. Immunohistochemical staining for CD31, α-SMA, and 5-HT was performed on spinal cord sections taken 42 days after SCI. Luxol fast blue staining was performed at Day 42. RESULTS Low-energy ESWT significantly improved not only locomotion but also mechanical and thermal allodynia following SCI. In the double staining, expression of VEGF was observed in NeuN-, GFAP-, and Olig2-labeled cells. Low-energy ESWT significantly promoted CD31 and α-SMA expressions in the injured spinal cords. In addition, low-energy ESWT significantly reduced the TUNEL-positive cells in the injured spinal cords. Furthermore, the immunodensity of 5-HT-positive axons was significantly higher in the animals treated by low-energy ESWT. The areas of spared white matter were obviously larger in the SCI-SW group than in the SCI group, as indicated by Luxol fast blue staining. CONCLUSIONS The results of this study suggested that low-energy ESWT promotes VEGF expression in various neural cells and enhances angiogenesis in damaged neural tissue after SCI. Furthermore, the neuroprotective effect of VEGF induced by low-energy ESWT can suppress cell death and axonal damage and consequently improve locomotor and sensory functions after SCI. Thus, low-energy ESWT can be a novel therapeutic strategy for treatment of SCI.
authors.affiliation: Departments of 1 Orthopaedic Surgery and.
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Yahata
authors.affiliation: Departments of 1 Orthopaedic Surgery and.
authors.forename: Haruo
authors.initials: H
authors.lastname: Kanno
authors.affiliation: Departments of 1 Orthopaedic Surgery and.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ozawa
authors.affiliation: Departments of 1 Orthopaedic Surgery and.
authors.forename: Seiji
authors.initials: S
authors.lastname: Yamaya
authors.affiliation: Departments of 1 Orthopaedic Surgery and.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Tateda
authors.affiliation: Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
authors.forename: Kenta
authors.initials: K
authors.lastname: Ito
authors.affiliation: Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Shimokawa
authors.affiliation: Departments of 1 Orthopaedic Surgery and.
authors.forename: Eiji
authors.initials: E
authors.lastname: Itoi
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D006930:Hyperalgesia / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D009043:Motor Activity / Q000502:physiology*; D018919:Neovascularization, Physiologic; D009474:Neurons / Q000378:metabolism / Q000473:pathology; D011897:Random Allocation; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function / Q000502:physiology; D013116:Spinal Cord / Q000098:blood supply / Q000473:pathology / Q000503:physiopathology; D013119:Spinal Cord Injuries / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy*; D013904:Thoracic Vertebrae; D014464:Ultrasonic Therapy; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*; D066127:White Matter / Q000098:blood supply / Q000473:pathology / Q000503:physiopathology
chemical_list: D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat
keywords: BBB = Basso-Beattie-Bresnahan; ESWT = extracorporeal shock wave therapy; PBS = phosphate-buffered saline; SCI = spinal cord injury; VEGF = vascular endothelial growth factor; extracorporeal shock wave therapy; spinal cord injury; vascular endothelial growth factor